Table 1.
Receptor binding affinity of ITI-007 as measured by radioligand displacement assays: comparison with antipsychotic and antidepressant medications
Receptor | ITI-007a | Risperidoneb | Olanzapineb | Aripiprazoleb | Fluoxetinec |
---|---|---|---|---|---|
5-HT2A | 0.5 | 0.5 | 2.5 | 9 | 141 |
D2 | 32 | 5.9 | 31 | 1.6 | >10,000 |
D1 | 52 | 564 | 128 | 1,170 | >10,000 |
SERT | 62 | >1,000 | >1,000 | 240–405 | 0.9–20 |
Ratios | |||||
D2/5-HT2A | 60 | 12 | 12.4 | 0.18 | >70 |
Receptor | |||||
H1 histamine | >1,000 | 14 | 2 | 28 | 1,240 |
5-HT2C | 173 | 63 | 7.1 | 130 | 69 |
α1 Adrenergic | 73 | 2.3 | 60 | 26 | 2,260 |
Ratios | |||||
H1/5-HT2A | >2,000 | 28 | 1 | 3 | 8.8 |
5-HT2C/5-HT2A | 320 | 126 | 3 | 14 | 0.5 |
α1/5-HT2A | 135 | 5 | 24 | 2.9 | 16 |
aBinding affinities were determined as described in the “Materials and Methods” section;
bBinding affinities for other compounds were derived from the NIMH Psychoactive Drug Screening Program (PDSP) Database (Roth et al. 2004)
cBinding affinities for fluoxetine at 5-HT2A (Owens et al. 1997), D2 (Sánchez and Hyttel 1999), D1 (Sánchez and Hyttel 1999), H1 (Owens et al. 1997, 2002), α1 adrenergic (Owens et al. 1997, 2002), and 5-HT2C receptors (Pälvimäki et al. 1996; Bonhaus et al. 1997; Rothman et al. 2000; Sánchez and Hyttel 1999), as cited by from the NIMH Psychoactive Drug Screening Program (PDSP) Database